Organisation paid for research Program year 2025 Source: CMS Open Payments

Jem Research LLC

Neither a doctor nor a teaching hospital

Research payments

$7,723,500

400 payments

Through program year 2025, Jem Research LLC is reported as receiving $7,723,500 in research payments, across 400 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$717,246	26
2024	Research	$337,819	37
2023	Research	$322,009	98
2022	Research	$146,563	25
2021	Research	$1,561,937	77
2020	Research	$2,993,660	69
2019	Research	$1,644,264	68

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $4,253,444 287 payments
Eli Lilly and Company $1,867,240 56 payments
Biogen, Inc. $1,309,344 5 payments
Amneal Pharmaceuticals LLC $130,696 19 payments
Pfizer Inc. $105,221 4 payments
Sunovion Pharmaceuticals Inc. $45,297 26 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $9,923 1 payment
AbbVie, Inc. $2,335 2 payments

Studies the money was for Research payments · program years 2019–2025

Assessment of Safety, Tolerability, and Efficacy of Ly3303560 in Early Symptomatic Alzheimer's Disease $1,257,695 6 payments
Phase II Study for Moderate Ad $1,170,738 93 payments
Pom Study of Brain Shuttle Gantenerumab in Early Ad $927,908 44 payments
A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205 $825,479 1 payment
Q1w Dosing $589,773 30 payments
Gantenerumab in Early Ad $560,155 15 payments
A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $420,701 42 payments
Phase II Study of Anti Tau in Prodromal to Mild Ad $418,067 32 payments
Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $415,346 1 payment
Assessment of Safety, Tolerability and Efficacy of Ly3002813 Alone and in Combination With Ly3202626 in Early Symptomatic Alzheimers Disease $228,469 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.